Sernova Corp.

TSX:SVA.TO

Biotechnology

Healthcare
$0.14 -5.88%

-$0.01 today

Market cap
$50.98M
Beta
0.66
P/E (TTM)
-4.7
EPS (TTM)
-$0.03
52W Low $0.12High $0.21

Volume 0.55M

Average 0.12M

SVA.TO Income Before Tax

Profit after all operating and non-operating items but before income tax.

Sernova Corp.TSX: SVA.TO

Income Before Tax · Q2 FY2026 · quarter ended Apr 2026

Income before tax remains negative

Q2 FY2026 income before tax was -CA$3.23M, compared with -CA$3.74M a year earlier. Trailing-twelve-month income before tax was -CA$11.91M.

Context

  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -CA$3.23M or moves back toward the trailing-twelve-month quarterly average of -CA$2.98M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
-CA$3.23M-34.3% QoQ
Last fiscal yearOct 2025
-CA$15.84M+50.8% YoY
LTMApr 2026
-CA$11.91M+45.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.6%——
1 year+50.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

CAD · from the income statement

Latest · FY2025
(15.84M) CAD
Year-over-year change
+50.8%

Income Before Tax vs competitors

How SVA.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +45.7% is the highest of 2, against a peer median of -57.7%.
SVA.TO Competitors
Income Before Tax for SVA.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SVA.TOSernova Corp.LTM Apr 2026-CA$11.91M CAD+45.7%——
BCT.TOBriaCell Therapeutics Corp.LTM Apr 2026-$30.95M USD-57.7%——
Peer median (excluding SVA.TO) —-57.7%——

Competitors are the stored peer set for SVA.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue267.2K440K445.55K540.28K342.59K
Gross Profit(267.2K)(440K)(445.55K)(540.28K)(342.59K)
Gross Margin—————
Research & Development4.64M16.9M32.26M22.36M7.28M
Selling, General & Admin2.29M7.83M8.46M8.97M7.5M
Operating Expenses6.94M24.75M41.13M31.84M14.78M
Depreciation & Amortization267.2K440K308.49K410.53K342.59K
EBITDA(6.6M)(24.54M)(40.19M)(31.25M)(14.74M)
EBITDA Margin—————
Operating Income(6.87M)(24.18M)(41.13M)(31.84M)(15.12M)
Operating Margin—————
Interest Income70.55K577.29K1.5M388.39K25.63K
Interest Expense58.37K118K32.08K586.86K754.81K
Other Income / Expenses1.09M1.01M1.5M(347.04K)(711.01K)
Income Before Tax(6.97M)(24.42M)(39.63M)(32.19M)(15.84M)
Pre-Tax Margin—————
Income Tax Expense58.37K118K(629.02K)7K(92.19K)
Net Income(7.02M)(24.54M)(39M)(32.19M)(15.74M)
Net Margin—————
EPS (Basic)(0.03)(0.09)(0.13)(0.10)(0.05)
EPS (Diluted)(0.03)(0.09)(0.13)(0.10)(0.05)
Weighted Avg Shares245.52M273.59M303.33M306.96M328.29M
Weighted Avg Shares (Diluted)245.52M273.59M303.33M306.95M328.29M

Sernova Corp.

TSX:SVA.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.